Endocrinology Medical News about Aortic Valve Stenosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

At Sea with SEAS: The First Clinical Endpoint Trial for Ezetimibe, Treatment of Patients with Mild to Moderate Aortic Stenosis, Ends with Mixed Results and More Controversy
Heart, Lung, and Circulation, 09/21/09

Hamilton–Craig I et al. – There was no difference in the primary endpoint (a combination of AVR, CV death, non–fatal MI, congestive heart failure from AS progression, coronary revascularisation, hospitalised unstable angina and non–haemorrhagic stroke). Compared with placebo, CVD events were reduced by 4.4% from 20.1% to 15.7% in the simvastatin/ezetimibe group. Cancer incidence and cancer deaths were more frequent in the simvastatin/ezetimibe group. These differences were not related to any form of cancer and did not increase with increased duration of therapy.

<< Previous
Understanding polycystic ovary syndrome

Next >>
Therapeutic potential for GIP receptor agonists and antagonists